How and Where Are Peptides Made? US vs China, Lab to Vial

How Are Peptides Made? The Science Behind Every Vial

Peptides are made by chemically linking amino acids in a precise sequence using solid-phase peptide synthesis (SPPS), a method invented by Robert Merrifield in 1963. Each amino acid is added one at a time to a resin support, with protecting groups preventing unwanted reactions, before the completed chain is cleaved, purified, and lyophilised.

Understanding how peptides are manufactured matters if you are serious about what goes into your body. The method used, the facility that runs it, and the country it ships from all determine the purity, potency, and safety of the final product. This guide covers the chemistry, the geography, and the quality controls you should demand.

Affiliate disclosure: this post contains affiliate links. If you purchase through our partner links, we may earn a commission at no extra cost to you.

What Is Solid-Phase Peptide Synthesis?

Solid-phase peptide synthesis (SPPS) anchors the first amino acid to an insoluble resin bead, then builds the peptide chain from the C-terminus to the N-terminus by coupling one protected amino acid at a time. Protecting groups block reactive side chains until the full sequence is assembled, then a cleavage step releases the crude peptide for purification.

The dominant modern protocol is Fmoc/tBu chemistry. Fmoc (9-fluorenylmethoxycarbonyl) shields the alpha-amine; tert-butyl (tBu) groups protect acid and hydroxyl side chains. Each coupling cycle uses activated carboxyl groups, typically via aminium-derived reagents such as HATU or HBTU, that drive fast, efficient bond formation with minimal racemisation. Behrendt 2008

The sequence of events for every single amino acid addition runs as follows:

1. Deprotection: piperidine removes the Fmoc group from the N-terminus of the growing chain.
2. Coupling: the next Fmoc-protected amino acid, activated with a coupling reagent, reacts with the free amine.
3. Capping: acetic anhydride caps any unreacted amines to prevent deletion sequences accumulating.
4. Wash: excess reagents are removed before the next cycle begins.

After all amino acids are coupled, the peptide is cleaved from the resin using trifluoroacetic acid (TFA), and the crude product undergoes preparative HPLC to remove impurities, deletion sequences, and oxidation products. Jaradat 2024

For peptides shorter than roughly 50 amino acids, SPPS is the clear method of choice. Longer sequences, or those requiring unusual ligation chemistry, may use native chemical ligation, which joins unprotected peptide fragments in aqueous solution. Dawson 2015

Microwave-Assisted SPPS: Speed and Purity Gains

Microwave-assisted SPPS reduces cycle time to as little as four minutes per amino acid, cutting total synthesis time for a 30-residue peptide from days to hours while achieving purity above 90% directly off the synthesiser. The energy input accelerates coupling and deprotection kinetics and suppresses aggregation in difficult sequences.

Conventional SPPS at room temperature struggles with sequences prone to beta-sheet aggregation on the resin. Elevated temperature under microwave irradiation disrupts those secondary structures and drives coupling to near-completion before side reactions accumulate. A 2014 study on high-efficiency SPPS reported a 4-minute cycle time, 90% waste reduction, and purities of 93% and 72% for acyl carrier protein (ACP) and beta-amyloid peptides respectively. Collins 2014

CEM Corporation scaled microwave synthesis to kilogram production in 2018, partnering with AmbioPharm in 2021 to bring the technology to commercial pharmaceutical manufacture. Microwave methods also make greener solvents more viable because higher temperatures compensate for the slower solvation kinetics of less polar alternatives to DMF.

A separate process innovation eliminates solvent-intensive washing steps entirely by using bulk evaporation with directed headspace gas flushing to remove the Fmoc deprotection base between cycles. Sharma 2023

The Environmental Cost of Peptide Manufacturing

SPPS carries a Process Mass Intensity (PMI) of approximately 13,000, meaning roughly 13,000 kg of raw materials are consumed per kilogram of peptide produced. That is around 40 times the PMI of small-molecule drugs and substantially higher than biopharmaceuticals. The bulk of that waste is organic solvents.

A 2024 analysis by 14 member companies of the ACS Green Chemistry Institute Pharmaceutical Roundtable examined 40 synthetic peptide processes across development stages. Solvents dominate the PMI calculation, with DMF, NMP, acetonitrile, and dichloromethane accounting for the largest proportion of mass input. Sherwood 2024

Innovations closing that gap include:

• Wash elimination protocols that remove DMF consumption by up to 90%.
• Microwave synthesis reducing overall solvent use per cycle.
• Switch to PEG-modified polystyrene resins that swell in greener solvents.
• Flow chemistry approaches that precisely meter reagents with less excess.

For the research consumer, environmental impact is a proxy metric for manufacturing discipline. Facilities managing PMI tightly tend to run cleaner processes with better batch-to-batch consistency.

Peptide Quality Control: What the Tests Actually Measure

Pharmaceutical-grade peptide quality control requires analysis of primary sequence, secondary structure, oligomerisation state, impurities, and degradation products using HPLC, mass spectrometry, NMR, and endotoxin assays. A single HPLC trace is not sufficient to confirm identity, purity, and safety simultaneously.

The FDA defines a peptide as a molecule containing 40 amino acids or fewer. Synthetic routes and recombinant DNA (rDNA) routes are treated as equivalent for regulatory purposes, and the same quality attributes must be demonstrated regardless of method. Morsa 2023

The quality attributes a compliant facility tests for include:

• Identity and sequence confirmation: LC-HRMS (liquid chromatography with high-resolution mass spectrometry) confirms the exact molecular mass and can detect single amino acid substitutions or deletions.
• Purity by HPLC: reversed-phase HPLC quantifies the main peak against related impurities. Pharmaceutical-grade targets 98% or higher; research-grade typically 95%+.
• Related impurities: deletion sequences, oxidised methionine, deamidated asparagine, insertion sequences. LC-HRMS can detect these below 0.1% level. Seger 2015
• Endotoxin (LAL test): bacterial lipopolysaccharides from manufacturing contaminants can trigger severe inflammatory responses. Endotoxin limits for injectable research compounds are typically below 1 EU/kg.
• Residual solvents: GC headspace analysis confirms DMF, acetonitrile, and TFA are below ICH Q3C limits.
• Water content: Karl Fischer titration measures residual moisture in lyophilised peptides, which affects stability and true potency per milligram.

Current Good Manufacturing Practice (cGMP) requires validated processes, personnel training, equipment calibration, environmental monitoring, and documented batch records for every production run. The FDA enforces these standards under 21 CFR Parts 210 and 211 and inspects manufacturing facilities worldwide. FDA 2025

For a deeper look at what these tests mean when evaluating a supplier, see our guide to peptide purity testing standards and what HPLC actually tells you.

Where Are Peptides Made? US vs China Compared

Most research peptides sold globally are manufactured in China, with a smaller number produced in the US and Europe. Chinese facilities range from cGMP-certified, FDA-inspected operations indistinguishable from Western standards, to low-tier repackagers operating with minimal quality oversight. Origin alone tells you nothing; certification tier and supply chain transparency tell you everything.

Chinese Peptide Manufacturing

China's dominance in peptide contract manufacturing stems from an integrated ecosystem. Raw material suppliers, synthesis equipment manufacturers, and finished peptide facilities cluster in cities like Hangzhou, Chengdu, and Shanghai, creating logistics and cost advantages that Western suppliers struggle to replicate. Costs run 30 to 60% lower than comparable Western manufacturing. SeekPeptides 2026

At the top tier, facilities like CPC Scientific in Hangzhou operate full cGMP lines and have passed four FDA inspections with zero Form 483 observations, the equivalent of a clean inspection report. CPC Scientific 2021 These facilities manufacture active pharmaceutical ingredients (APIs) for US and European drug companies, hold ISO 13485 medical device management certification, and produce peptides to 99% purity with full documentation packages.

The quality problem in Chinese peptide supply chains is not the top-tier manufacturers. It is the layers of intermediaries between a synthesis facility and the end consumer. A peptide synthesised to 98% purity at a cGMP facility can pass through a broker, a repackager, and a distributor before it reaches a vial with a vendor label on it. Each handoff is a point where documentation can be lost, batches can be blended, or cold chain requirements can be violated. [Anecdote: experienced researchers report significant batch-to-batch variation from vendors that cannot provide original CoA documentation traceable to the synthesis facility.]

US and European Peptide Manufacturing

US-based peptide contract manufacturers, such as AmbioPharm (South Carolina) and Bachem (with US operations), produce primarily to pharmaceutical GMP standards for drug development clients. The regulatory environment, labour costs, and facility overhead mean US-manufactured peptides carry substantially higher prices, which is why relatively few research-use peptides originate from US synthesis.

The FDA restricted certain injectable peptides in 2023, citing safety concerns including cancer, liver, kidney, and heart risks. The compounding industry has argued that these restrictions pushed demand toward unregulated import channels that bypass US quality standards entirely. PBS NewsHour 2026 That regulatory landscape remains in flux as of mid-2026.

European manufacturers operate under EMA oversight and ICH guidelines. The EMA released a draft guideline on synthetic peptide drug quality in April 2024, tightening requirements for impurity characterisation and stability data. ICH's consensus framework on quality, stability, and impurity control is adopted by PMDA (Japan), NMPA (China), MHRA (UK), and TGA (Australia). Peptide Chemistry 2025

How to Evaluate a Peptide Supplier's Manufacturing Claims

The only reliable way to evaluate a peptide supplier is to review third-party certificates of analysis that trace back to an identifiable synthesis facility, confirm the testing methods used match the compound, and verify the purity figure reflects the correct measurement technique. Marketing language about "pharmaceutical grade" or "99% pure" is meaningless without supporting documentation.

A credible supplier for research use should be able to provide:

• A certificate of analysis (CoA) with lot number, synthesis date, and the name of the testing laboratory.
• HPLC trace confirming purity, with peak assignment and baseline separation clearly visible.
• Mass spectrometry (MS) data confirming the molecular weight matches the theoretical value for the stated sequence.
• Endotoxin test result, particularly critical for any injectable application.
• Residual solvent data if the compound is for sensitive applications.

Ask whether the CoA comes from an independent third-party laboratory or from the manufacturer's own in-house QC. Third-party testing from an accredited laboratory with no commercial relationship to the vendor is the gold standard.

For further context on what to look for in documentation, our overview of what peptides are and how the amino acid sequence determines function explains the structural basis for why impurities matter biologically.

If you are sourcing research peptides, RealPeptides provides third-party tested compounds with traceable CoA documentation. Browse RealPeptides' research compound catalogue here.

The Future of Peptide Manufacturing

Peptide manufacturing is undergoing its most significant technological shift since Merrifield's resin synthesis. Continuous flow chemistry, microwave scale-up, solvent reduction technologies, and tightening global regulatory harmonisation are converging to raise quality floors and reduce the gap between top-tier and mid-tier facilities over the next five years.

Key trends shaping the field:

• Flow chemistry: continuous-flow SPPS replaces batch reactors with precise reagent metering, reducing excess and improving consistency at scale.
• Green solvents: DMF replacement with 2-MeTHF and Cyrene is advancing as microwave methods lower the temperature barrier for alternative solvents.
• AI-assisted sequence optimisation: machine learning models predict aggregation-prone sequences and recommend protecting group strategies before synthesis begins, reducing failed runs.
• Regulatory harmonisation: the EMA's April 2024 draft guideline signals tighter alignment between US and European standards for peptide drug quality, narrowing the gap that currently allows research-use compounds to escape pharmaceutical scrutiny.

For the research community, tightening manufacturing standards globally is positive. The quality floor rises even for non-pharmaceutical-grade synthesis as the analytical tools, regulatory expectations, and competitive pressure from top-tier facilities propagate through the supply chain.

References

• Sherwood et al. (2024). Process Mass Intensity: A Holistic Analysis of Peptide Manufacturing Processes. ACS GCI Pharmaceutical Roundtable.
• Behrendt et al. (2008). Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences.
• Sharma et al. (2023). Total wash elimination for solid phase peptide synthesis.
• Dawson (2015). Solid phase protein chemical synthesis.
• Jaradat (2024). Safety-Catch Linkers for Solid-Phase Peptide Synthesis.
• Collins et al. (2014). High-efficiency solid phase peptide synthesis (HE-SPPS).
• Seger et al. (2015). Liquid Chromatography-High Resolution Mass Spectrometry for Peptide Drug Quality Control.
• Morsa et al. (2023). Reference Standards to Support Quality of Synthetic Peptide Therapeutics.
• FDA (2025). Facts About Current Good Manufacturing Practice (CGMP).
• Peptide Chemistry (2025). Peptide Drug Development Regulations: EMA, FDA, and ICH.
• SeekPeptides (2026). Chinese Peptides: Complete Sourcing Guide For Researchers.
• CPC Scientific (2021). CPC Scientific Successfully Passes 4th U.S. FDA Inspection.
• PBS NewsHour (2026). FDA to Weigh Easing Limits on Unproven Peptides.
• Kulkarni et al. (2019). Chemical Methods for Peptide and Protein Production.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.